Want to see AU:IVX full AI Analyst Report?
Top Page
Invion
(Sydney:IVX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.03
▼(-57.50% Downside)
Action:Reiterated
Date:06/30/26
The score is primarily weighed down by very weak financial performance (revenue dropping to zero, widening losses, and ongoing cash burn alongside shrinking equity). With no usable technical indicators, the technical view is neutral, and valuation is constrained by a negative P/E and lack of dividend yield data.
Positive Factors
Conservative capital structure (no debt)
A debt-free balance sheet reduces fixed interest obligations and improves downside resilience, giving management flexibility to pursue partnerships or staged development financing. Over 2-6 months this lowers bankruptcy risk and preserves cash for R&D or milestone work without interest service constraints.
Negative Factors
Revenue collapse to zero in FY2025
A complete revenue drop in the latest fiscal year is a structural signal of project delays, contract loss, or commercialization failure. Over the medium term it undermines ability to self-fund operations, weakens partner negotiating leverage, and increases probability of needing dilution or expensive external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative capital structure (no debt)
A debt-free balance sheet reduces fixed interest obligations and improves downside resilience, giving management flexibility to pursue partnerships or staged development financing. Over 2-6 months this lowers bankruptcy risk and preserves cash for R&D or milestone work without interest service constraints.
Read all positive factors
Invion (IVX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.37M
Dividend YieldN/A
Average Volume (3M)97.01K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-100.00%
EPS Growth-31.21%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.13
Shares Outstanding109,200,640
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invion Business Overview & Revenue Model
Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent be...
How the Company Makes Money
Invion generates revenue through development funding and licensing agreements. The company's key partnerships, including those with strategic research collaborators, are significant contributors to its earnings, where these collaborators fund its ...
Invion Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 3.69M | 4.10M | 3.29M | 2.33M |
| Gross Profit | -1.59M | -1.29M | 1.00M | 1.21M | 969.12K | 810.50K |
| EBITDA | -5.16M | -4.00M | -4.57M | -965.37K | -1.82M | -1.29M |
| Net Income | -10.50M | -8.81M | -5.63M | -1.61M | -2.24M | -1.48M |
Balance Sheet | ||||||
| Total Assets | 8.09M | 9.49M | 15.45M | 19.05M | 20.04M | 5.64M |
| Cash, Cash Equivalents and Short-Term Investments | 137.54K | 850.37K | 783.53K | 4.08M | 8.47M | 1.04M |
| Total Debt | 627.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.38M | 1.24M | 1.01M | 650.63K | 462.41K | 851.50K |
| Stockholders Equity | 5.71M | 8.25M | 14.44M | 18.40M | 19.58M | 4.79M |
Cash Flow | ||||||
| Free Cash Flow | -2.61M | -2.97M | -3.30M | -4.39M | -8.36M | 417.98K |
| Operating Cash Flow | -2.61M | -2.97M | -2.40M | -1.81M | -1.11M | 417.98K |
| Investing Cash Flow | -22.68K | 0.00 | -900.00K | -2.58M | -7.25M | 0.00 |
| Financing Cash Flow | 2.04M | 3.04M | 0.00 | 15.80M | 15.80M | 0.00 |
Invion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$43.94M | -101.28 | -0.79% | ― | 6.80% | 98.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$6.09M | -0.36 | -110.74% | ― | ― | 49.10% | |
42 Neutral | AU$4.37M | -0.26 | -150.48% | ― | -100.00% | -31.21% | |
42 Neutral | AU$19.73M | -5.07 | 4388.00% | ― | -53.90% | 57.52% | |
42 Neutral | AU$13.57M | -2.17 | -29.05% | ― | 6.14% | -20.00% | |
41 Neutral | AU$4.11M | -0.12 | 182.89% | ― | 17.56% | 75.11% |
* Healthcare Sector Average
AU:IVX
Invion
0.04
-0.08
-68.18%
AU:PER
Percheron Therapeutics
0.01
0.00
0.00%
AU:RGT
Argent Biopharma
0.04
-0.04
-54.32%
AU:MVP
Medical Developments International Limited
0.40
-0.16
-28.18%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-32.00%
AU:IDT
IDT Australia Limited
0.03
-0.06
-64.04%
Invion Corporate Events
Invion Issues New Tranches of Unquoted Options to Strengthen Capital Structure
Jun 22, 2026
Invion Limited has notified the market of the issuance of new unquoted options as part of its ongoing equity arrangements. The company lodged an Appendix 3G detailing these securities, which are not intended to be quoted on the ASX, underscoring i...
Invion Seeks ASX Quotation for New Series of Options
Jun 22, 2026
Invion Limited has applied for quotation on the ASX of 1,564,508 options, designated as IVXO and expiring on 30 June 2027, with an issue date of 19 June 2026. The options form part of a previously announced transaction, indicating Invion is progre...
Invion boosts PDT push with appointment of global clinical leader Colin Hopper
Jun 21, 2026
Invion has appointed Dr Colin Hopper, a globally recognised leader in photodynamic therapy and president of the International Photodynamic Association, as Clinical Advisor to support development of its Photosoft NGPDT platform. Hopper will guide c...
Invion boosts director equity stake with new incentive options
Jun 19, 2026
Invion has disclosed a change in director Alistair Bennallack’s interests following the issue of new incentive options and options in lieu of directors’ fees, as approved at the company’s annual general meeting on 29 May 2026. Be...
Invion Issues 671,882 Unquoted Convertible Notes as Part of Funding Strategy
Jun 16, 2026
Invion Limited has notified the market of the issue of 671,882 unquoted convertible notes, designated under ASX security code IVXAAQ, effective 16 June 2026. The new securities form part of previously flagged capital arrangements and are not inten...
Invion secures strong shareholder backing for capital measures at EGM
May 29, 2026
Invion shareholders have strongly backed a suite of capital and transaction resolutions at an extraordinary general meeting, including approval of a proposed transaction and the issue of consideration shares. The voting outcomes, with support gene...
Invion corrects director shareholding disclosure in ASX filing
May 11, 2026
Invion Limited has disclosed that an indirect shareholding of director Alistair Bennallack, held via a superannuation fund, was omitted from earlier director interest notices lodged in 2020 and 2025, and has now filed a corrected Appendix 3Y with ...
Invion Options Lapse, Trimming Potential Future Dilution
May 1, 2026
Invion Limited has reported a change in its capital structure relating to listed options on the Australian Securities Exchange. The company advised that a series of options with a $1.00 exercise price, due to expire on 1 May 2026, have lapsed unex...
Invion bolsters funding as Photosoft cancer programs show promising progress
Apr 30, 2026
Invion reported a modest cash balance at the end of the March quarter, supported by a two-tranche $1.3 million convertible note offering backed by its executive chair and a major shareholder, to fund ongoing cancer trials, partner-supported studie...
Invion convenes virtual general meeting to vote on fair and reasonable transaction
Apr 28, 2026
Invion Limited has called a virtual General Meeting of shareholders to be held on 29 May 2026 at 4:00pm AEST, using online conferencing technology that allows real-time questions and poll-based voting. Shareholders are encouraged to register in ad...
Invion to Showcase Photodynamic Cancer Therapy at Major Asian Biotech Conferences
Apr 21, 2026
Invion Limited, the ASX-listed life-science company developing Photosoft-based next generation photodynamic therapy for cancer and infectious diseases, is expanding its international profile through a series of conference appearances. The company&...
Invion Expands INV043 Skin Cancer Trial to Basal Cell Carcinoma After Strong Safety Data
Apr 21, 2026
Invion has advanced its clinical program for INV043 in non-melanoma skin cancer by progressing to the final phase of its current trial and expanding enrolment to patients with basal cell carcinoma. This move follows approval from the Safety Review...
Invion Updates Director Interest Disclosure to Strengthen Governance
Apr 20, 2026
Invion has clarified that earlier director interest notices for executive chair and CEO Thian Chew did not include certain interests held by substantial shareholder Honsue Cho and his associates, as these were not strictly required under ASX Listi...
Invion Updates Market on Director Chiat Thian Chew’s Expanded Associated Holdings
Apr 20, 2026
Invion Limited has disclosed changes to the relevant interests of director Chiat Thian Chew in the company’s securities, as required under ASX listing rules. The notice details both his direct holdings in ordinary shares and unlisted options...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.